依普利酮对高血压有多大的疗效？

A selective aldosterone receptor antagonist developed by Pfizer of the United States, the trade name is Planep.

Aldosterone is an important component in the renin-angiotensin-aldosterone system (RAAS) and plays an important role in the regulation of the human cardiovascular system. According to the American Journal of Hypertension, the selective aldosterone receptor blocker eplerenone can effectively control mild to moderate hypertension and is well tolerated.

Studies have shown that eplerenone can cause a sustained increase in plasma renin and serum aldosterone, and at the same time block the feedback regulatory effect of aldosterone. However, the increase in plasma renin activity and the increase in systemic circulation aldosterone levels will not offset the blood pressure control effect of this product. Eplerenone and spironolactone work on the same principle. Long-term use of spironolactone can cause endocrine disorders, while eplerenone has good tolerance and has the advantage of having few side effects, avoiding the side effects of endocrine disorders.

Eplerenone selectively acts on aldosterone receptors and is highly selective for mineralocorticoid receptors, but has less effect on androgen and progesterone receptors. Its affinity for mineralocorticoids is 15 to 20 times that of spironolactone, while its affinity for androgen and progesterone receptors is 500 times smaller than that of spironolactone, so sex hormone-related adverse reactions are less likely to occur.

In the treatment of patients with stage 1 and stage 2 hypertension, the effective rate and magnitude of reducing systolic blood pressure and diastolic blood pressure are similar to those of enalapril. Eplerenone also has a good antihypertensive effect in patients with essential hypertension with low renin levels for whom angiotensin-converting enzyme inhibitors and angiotensin II receptor inhibitors are not effective. It also has a good antihypertensive effect on simple systolic hypertension, and has a good antihypertensive effect on diet-induced obesity-related hypertension. In addition, eplerenone can significantly reduce the ultrafiltration effect of glomeruli and reduce albuminuria in patients with hypertension. This renal protective effect is more obvious for hypertensive patients with diabetes.